Chiron cuts vaccine projections

Shares of Chiron dropped this morning after the company announced that production delays and manufacturing issues forced it to project a shortfall in vaccine production and revenue. Chiron cut its forecast of 25 million to 30 million doses of flu vaccine to 18 million to 26 million. The move comes after Chiron was forced to shutter its vaccine plant in the UK last fall after British regulators discovered contamination problems in the plant.

- read this story from the AP for more

Suggested Articles

A phase 3 study of NuCana’s lead drug was halted because a monitoring committee deemed it unlikely to succeed.

The filing follows data from Japanese phase 3 trials that assessed the oral HIF-PHI in chronic kidney disease patients.

The Allen Institute found major differences in human and mouse brain cells, which could guide the design of drugs for brain diseases.